Clover Health Investments, Corp.
Clover Health Investments, Corp. CLOV Peers
See (CLOV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CLOV | $2.81 | +0.54% | 1.4B | -69.00 | -$0.04 | N/A |
| UNH | $310.17 | +2.49% | 280.4B | 12.94 | $23.89 | +2.77% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.76% |
| CI | $329.19 | -0.25% | 87.2B | 18.20 | $17.93 | +1.77% |
| CVS | $68.56 | +0.62% | 86.6B | 16.34 | $4.19 | +3.89% |
| ELV | $387.46 | +3.83% | 86.2B | 14.85 | $25.69 | +1.76% |
| HUM | $242.48 | +1.08% | 29.2B | 17.07 | $14.16 | +1.47% |
| CNC | $53.48 | -0.17% | 26.9B | 7.93 | $6.81 | N/A |
| MOH | $295.57 | +1.55% | 16.1B | 14.33 | $20.71 | N/A |
| OSCR | $21.25 | +3.76% | 5.2B | 51.03 | $0.40 | N/A |
Stock Comparison
CLOV vs UNH Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, UNH has a market cap of 280.4B. Regarding current trading prices, CLOV is priced at $2.81, while UNH trades at $310.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas UNH's P/E ratio is 12.94. In terms of profitability, CLOV's ROE is -0.07%, compared to UNH's ROE of +0.24%. Regarding short-term risk, CLOV is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs ANTM Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CLOV is priced at $2.81, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CLOV's ROE is -0.07%, compared to ANTM's ROE of +0.14%. Regarding short-term risk, CLOV is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.
CLOV vs CI Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, CI has a market cap of 87.2B. Regarding current trading prices, CLOV is priced at $2.81, while CI trades at $329.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas CI's P/E ratio is 18.20. In terms of profitability, CLOV's ROE is -0.07%, compared to CI's ROE of +0.12%. Regarding short-term risk, CLOV is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs CVS Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, CVS has a market cap of 86.6B. Regarding current trading prices, CLOV is priced at $2.81, while CVS trades at $68.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas CVS's P/E ratio is 16.34. In terms of profitability, CLOV's ROE is -0.07%, compared to CVS's ROE of +0.07%. Regarding short-term risk, CLOV is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs ELV Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, ELV has a market cap of 86.2B. Regarding current trading prices, CLOV is priced at $2.81, while ELV trades at $387.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas ELV's P/E ratio is 14.85. In terms of profitability, CLOV's ROE is -0.07%, compared to ELV's ROE of +0.14%. Regarding short-term risk, CLOV is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs HUM Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, HUM has a market cap of 29.2B. Regarding current trading prices, CLOV is priced at $2.81, while HUM trades at $242.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas HUM's P/E ratio is 17.07. In terms of profitability, CLOV's ROE is -0.07%, compared to HUM's ROE of +0.10%. Regarding short-term risk, CLOV is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs CNC Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, CNC has a market cap of 26.9B. Regarding current trading prices, CLOV is priced at $2.81, while CNC trades at $53.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas CNC's P/E ratio is 7.93. In terms of profitability, CLOV's ROE is -0.07%, compared to CNC's ROE of +0.13%. Regarding short-term risk, CLOV is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs MOH Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, MOH has a market cap of 16.1B. Regarding current trading prices, CLOV is priced at $2.81, while MOH trades at $295.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas MOH's P/E ratio is 14.33. In terms of profitability, CLOV's ROE is -0.07%, compared to MOH's ROE of +0.26%. Regarding short-term risk, CLOV is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs OSCR Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, OSCR has a market cap of 5.2B. Regarding current trading prices, CLOV is priced at $2.81, while OSCR trades at $21.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas OSCR's P/E ratio is 51.03. In terms of profitability, CLOV's ROE is -0.07%, compared to OSCR's ROE of +0.11%. Regarding short-term risk, CLOV is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.
CLOV vs ALHC Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, ALHC has a market cap of 2.7B. Regarding current trading prices, CLOV is priced at $2.81, while ALHC trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas ALHC's P/E ratio is -29.47. In terms of profitability, CLOV's ROE is -0.07%, compared to ALHC's ROE of -0.81%. Regarding short-term risk, CLOV is more volatile compared to ALHC. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs BHG Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CLOV is priced at $2.81, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas BHG's P/E ratio is -0.12. In terms of profitability, CLOV's ROE is -0.07%, compared to BHG's ROE of -0.47%. Regarding short-term risk, CLOV is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.
CLOV vs BMGL Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, BMGL has a market cap of 32.9M. Regarding current trading prices, CLOV is priced at $2.81, while BMGL trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas BMGL's P/E ratio is 19.44. In terms of profitability, CLOV's ROE is -0.07%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, CLOV is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.
CLOV vs MRAI Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, MRAI has a market cap of 18M. Regarding current trading prices, CLOV is priced at $2.81, while MRAI trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas MRAI's P/E ratio is -0.41. In terms of profitability, CLOV's ROE is -0.07%, compared to MRAI's ROE of +0.75%. Regarding short-term risk, CLOV is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.
CLOV vs IVF Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, IVF has a market cap of 2M. Regarding current trading prices, CLOV is priced at $2.81, while IVF trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas IVF's P/E ratio is -0.03. In terms of profitability, CLOV's ROE is -0.07%, compared to IVF's ROE of -2.58%. Regarding short-term risk, CLOV is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.
CLOV vs NIVF Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, NIVF has a market cap of 752.2K. Regarding current trading prices, CLOV is priced at $2.81, while NIVF trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas NIVF's P/E ratio is N/A. In terms of profitability, CLOV's ROE is -0.07%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, CLOV is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.
CLOV vs GTS Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CLOV is priced at $2.81, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas GTS's P/E ratio is 10.41. In terms of profitability, CLOV's ROE is -0.07%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CLOV is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.
CLOV vs MGLN Comparison
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 1.4B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CLOV is priced at $2.81, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -69.00, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CLOV's ROE is -0.07%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CLOV is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.